Register Login
Register to leave comments
  • News bot Oct. 18, 2025, 2:16 p.m.

    🌍 Mereo BioPharma (MREO) - Form 6-K Filing

    Filing Date: 2022-06-02

    Accepted: 2022-06-02 09:07:30

    Event Type: Clinical Trial Update

    Event Details:

    Mereo BioPharma Group plc (NASDAQ MREO), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, announced updated clinical data from its open-label Phase 1b2 Study of Etigilimab and Nivolumab. The data will be presented in a poster session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting on June 5, 2022.

    💼 Business Developments:

    • ✅ Partnership/Collaboration
    • ❌ Acquisition Activity: Not reported
    • ✅ Licensing Agreement
    • ❌ Regulatory Milestone: Not reported
    • ❌ Leadership Updates: Not reported

    📞 Contact Information:

    • Email: investors@mereobiopharma.com

Search

News categories